Table 2.
Demographic and substance use variables associated with HCV/HIV co-infection and HCV mono-infection in backward stepwise multinomial regression analysis
| AOR | 95%CI | |
|---|---|---|
| HCV and HIV co-infection |
|
|
| Shared syringesa |
27.72 |
13.30-57.76 |
| Number of MMTP enrollments (per time increase) |
2.28 |
1.33-3.90 |
| Number of times incarcerated (per time increase) |
2.01 |
1.71-2.37 |
| Smoking amphetaminea |
0.44 |
0.25-0.76 |
| HCV mono-infection |
|
|
| Number of times incarcerated (per time increase) |
1.77 |
1.52-2.06 |
| Length of drug injection (per year increase) |
1.04 |
1.01-1.07 |
| Smoking amphetaminea |
0.49 |
0.32-0.75 |
| Positive amphetamine urine drug screenb | 0.61 | 0.40-0.93 |
Reference is HCV/HIV-seronegative cases.
AOR, adjusted odds ratio. CI, confidence interval. HCV, hepatitis C virus. HIV, human immunodeficiency virus. MMTP, methadone maintenance treatment program.
a During the 6 months before enrollment in the MMTP.
b At the time of enrollment in the MMTP.